Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Wayfair Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $111.12 (market cap $12.58B), while Wayfair Inc trades at $104.8 (market cap $14.40B). The key difference: Halozyme Therapeutics Inc. Common Stock and Wayfair Inc are close in size by market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Wayfair Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Wayfair Inc for 8 Days on average.
| HALO | W | |
|---|---|---|
Market Cap | $12.58B | $14.40B |
Volume | 2,179,278 | 2,102,856 |
Sector | Health | Consumer Cyclical |
52-Week High | $115.22 | $119.05 |
52-Week Low | $61.63 | $57.40 |
Typical Hold Time | 0 Days | 8 Days |
Enterprise Value | $14.49B | $16.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Wayfair (W) trades at $104.47, down 0.93% on the day, showing mixed technical signals with a bullish moving average trend but neutral oscillators. Fundamentally, the company reported $12.46B revenue for 2025 but posted a net loss of $313M, with negative profit margins. Recent earnings show volatility, beating estimates in Q4 2025 and Q2 2026 but missing in Q1 2026. Analyst sentiment remains positive with a 54% buy rating and $114.13 consensus price target, while the company expands physically with new store openings.
The outlook for Wayfair hinges on improving profitability amid ongoing losses. Near-term catalysts include Q3 2026 earnings on November 4, 2026, where meeting the $0.785 EPS estimate could boost sentiment. Risks include high debt-to-asset ratio of 95.11% and competitive pressures in online retail. The stock offers 9.2% upside to the consensus target, but investors should monitor cash flow trends after 2026's negative net cash flow of $261M.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
